MIGENIX REPORTS THIRD QUARTER FISCAL YEAR 2006 RESULTS

Migenix Inc., a clinical-stage developer of drugs for infectious and degenerative diseases, reports financial results for the three and nine months ended January 31, 2006 and an update on its programs: Jim DeMesa, M.D., President & CEO of Migenix stated, "We continue to make excellent progress in our development programs, with two phase II clinical outcomes expected this year in our MX-3253 program for the treatment of chronic hepatitis C virus infections and a phase III clinical outcome for CPI-226 in catheter-related infections in the first half of calendar 2007.

MSN Money (http://news.moneycentral.msn.com/provider/providerarticle.asp?feed=PR&Date=20060308&ID=5565163)